Company
Headquarters: Riyadh, Saudi Arabia
SR15.50 Billion
SAR as of Jan. 1, 2025
US$4.13 Billion
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Dallah Healthcare Company provides and operates healthcare programs and utilities in the Kingdom of Saudi Arabia. The company engages in operating, managing, equipping, and developing hospitals and healthcare facilities, medical policlinics, compounds, and lands; and the provision of manpower and support services to hospitals and medical centers. It also manufactures and distributes pharmaceutical, herbal, and cosmetic products to retail pharmacies, health and beauty stores, hospitals, and governmental agencies. In addition, the company engages in the management and operation of hospitals owned by third parties; and the provision of other support services. Further, it manages private hospitals, medical and diagnostic centers, and an analytical laboratory; and provides medical services. The company was formerly known as Dallah Healthcare Holding Company and changed its name to Dallah Healthcare Company in November 2016. The company was founded in 1994 and is based in Riyadh, Saudi Arabia. Dallah Healthcare Company is the subsidiary of Dallah Al-Barakah Holding.
Top 1-year algo backtest: +327.04%
$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
| Last Financial Reports Date | Sept. 30, 2024 |
| Revenue TTM | SR3.20 B |
| EBITDA | SR782.9 M |
| Gross Profit TTM | SR1.08 B |
| Profit Margin | 14.70% |
| Operating Margin | 19.04% |
| Quarterly Revenue Growth | 13.10% |
Dallah Healthcare Company has the following listings and related stock indices.
Stock: Tadawul: 4004 wb_incandescent